Medtronic invos™ 7100 cerebral/somatic oximetry system receives 510(k) clearance for pediatric indications

Fda clearance expands use of the invos™ 7100 system, helping clinicians better monitor organ-specific oxygen levels and identify warnings signs for neonates and children earlier dublin, dec. 14, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced that the u.s. food and drug administration (fda) has granted 510(k) clearance for its invos™ 7100 cerebral/somatic oximetry system for children from birth through age 18. the invos system picks up key signals to inform time-critical decisions by pediatric clinicians related to hemodynamic management, ventilation, and resuscitation for premature infants, neonates, children, and other patients treated by pediatric clinicians.
MDT Ratings Summary
MDT Quant Ranking